Latest News

The FDA granted approval daratumumab and hyaluronidase combined with bortezomib, lenalidomide, and dexamethasone for induction and consolidation for patients with newly diagnosed multiple myeloma eligible for ASCT.

Response-adapted ultralow-dose therapy for patients with indolent orbital B-cell lymphoma demonstrated reduced radiation exposure, insignificant toxic effects, and superior disease outcomes, according to results from a phase 2 trial.

According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.

According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.

According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...

A shorter monitoring period may be reasonable for patients with relapsed/refractory multiple myeloma who underwent CAR-T therapy following results that suggest a low risk of cytokine release syndrome and immune effector cell-associated...

According to a prospective analysis, a combined use of TCR-triggered T-cell and FcR-triggered NK-cell exocytosis assays demonstrated efficacy in diagnosing familial hemophagocytic lymphohistiocytosis and defects in lymphocyte exocytosis.

According to results from a first-in-human, phase 1 study, SHR-A1811 demonstrated promising antitumor activity with acceptable safety and tolerability among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors.

According to results from a phase 2 trial, brentuximab vedotin and ibrutinib therapy demonstrated activity among patients with R/R Hodgkin lymphoma, however the combination cannot be recommended for future therapeutic development due to...

The combination of low-dose ruxolitinib and anti-interferon-gamma antibody emapalumab demonstrated efficacy and safety for treating patients with hemophagocytic lymphohistiocytosis, according to a retrospective analysis.